Pulmonary Hypertension Roundtable: Prognostic Indicators for Pulmonary Hypertension

2015 ◽  
Vol 14 (1) ◽  
pp. 48-53

Advances in Pulmonary Hypertension editor-in-chief Charles Burger, MD, Professor of Medicine at Mayo Clinic College of Medicine and Medical Director, PH Clinic, Mayo Clinic, Jacksonville, Florida, convened this issue's guest editors Ioana Preston, MD, Co-director, Pulmonary Hypertension Center, Tufts Medical Center, Boston, and Raymond Benza, MD, Program Director, Heart Failure, Transplant, Mechanical Circulatory Devices and Pulmonary Hypertension, Western Pennsylvania Allegheny Health System, and Professor of Medicine, Temple University, Pittsburgh, along with editorial board member Jonathan Rich, MD, Assistant Professor of Medicine, Northwestern University Feinberg School of Medicine, Medical Director, Mechanical Circulatory Support Program, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Chicago, for a wide-ranging discussion about clinicians' ability to prognosticate about patients' disease.

2012 ◽  
Vol 11 (3) ◽  
pp. 135-140

As a way to integrate the presentations at PHA's June scientific sessions with clinical practice, Guest Editor Karen Fagan, MD, convened a group of attendees to discuss their experience in Orlando. The discussants included Todd Bull, MD, Associate Professor, Medical Director, Anschutz Intensive Care Unit, University of Colorado, Aurora, Colorado; Anna Hemnes, MD, Assistant Director, Center for Adult Pulmonary Vascular Disease, Vanderbilt University, Nashville, Tennessee; C. Gregory Elliott, MD, Professor of Medicine, University of Utah and Medical Director, Pulmonary Hypertension Center, Intermountain Medical Center, Murray, Utah; Vinicio A. de Jesus Perez, MD, Assistant Professor in Medicine and Staff Physician, Wall Center Adult PH Clinic, Stanford University Medical Center, Palo Alto, California; and Paul B. Yu, MD, PhD, Brigham and Women's Hospital, Boston, Massachusetts.


2013 ◽  
Vol 12 (2) ◽  
pp. 88-93

On August 16, 2013, a group of physicians with clinical expertise related to management of pulmonary hypertension (PH) patients who are undergoing evaluation for or having liver or kidney transplantation was convened by telephone to discuss this challenging topic. These complex patients represent a spectrum of clinical types of PH and require complete evaluations utilizing a team-oriented and multidisciplinary approach to ensure appropriate treatment and safe transplantation. Facilitated by the guest editors of this issue, Charles Burger, MD, and Paul Forfia, MD, discussants included Michael Krowka, MD, Professor of Medicine, Pulmonary Division, Mayo Clinic, Rochester, Minnesota; José Diaz-Gómez, MD, Medical Director-ICU, Departments of Anesthesiology and Critical Care, Mayo Clinic, Jacksonville, Florida; Anna Hemnes, MD, Assistant Professor, Assistant Director, Pulmonary Vascular Disease Program Vanderbilt University Medical Center, Nashville, Tennessee; and Michael Mathier, MD, Assistant Professor of Medicine, Director, Pulmonary Hypertension Program, and Associate Director, Cardiovascular Fellowship Program of the University of Pittsburgh Medical Center.


2004 ◽  
Vol 3 (1) ◽  
pp. 20-25
Author(s):  
Victor Tapson ◽  
Robert Frantz ◽  
John Conte

This discussion was moderated by Victor Tapson, MD, Editor-in-Chief of Advances in Pulmonary Hypertension and Associate Professor, Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina. The participants included Robert Frantz, MD, Assistant Professor of Medicine, Cardiovascular Division, Mayo Clinic, Rochester, Minnesota; and John Conte, MD, Associate Professor of Surgery and Director of Heart and Lung Transplantation, Johns Hopkins University, Baltimore, MD.


2012 ◽  
Vol 11 (1) ◽  
pp. 41-46
Author(s):  
R. James White ◽  
Mardi Gomberg-Maitland ◽  
Jeremy Feldman ◽  
Ioana Preston ◽  
Steve Mathai

We invited 4 experts to a telephone roundtable facilitated by guest editor Jim White, MD, PhD, on April 13, 2012, to discuss the results of the recent Phase III trial, the Imatinib in Pulmonary Arterial Hypertension (IMPRES) trial (NCT00902174). Investigators enrolled patients with pulmonary arterial hypertension with severe hemodynamic impairment at catheterization despite treatment with 2 background therapies. Patients were randomized to placebo or 200 mg imatinib twice daily for 6 months of therapy to assess efficacy. Participating in the discussion were Mardi Gomberg-Maitland, MD, MSc, Associate Professor of Medicine and Director, Pulmonary Hypertension Center, University of Chicago; Iona Preston, MD, Co-director, Pulmonary Hypertension Center, Tufts University Medical Center, Boston; Jeremy Feldman, MD, Director, Pulmonary Hypertension Program, Medical Director of Research, Arizona Pulmonary Specialists, Phoenix; Stephen Mathai, MD, MHS, Assistant Professor of Medicine, The Johns Hopkins School of Medicine, Baltimore.


2007 ◽  
Vol 6 (2) ◽  
pp. 92-95
Author(s):  
Richard Channick ◽  
Kenneth R. McCurry ◽  
Ronald Pearl ◽  
Stuart Rich

This discussion was moderated by Richard Chan-nick, MD, Associate Professor of Medicine, Pulmonary and Critical Care Division, University of California, San Diego Medical Center, San Diego, California. Panel members included Kenneth R. McCurry, MD, Assistant Professor of Surgery, Division of Cardiothoracic Surgery, Director, Lung and Heart-Lung Transplantation Programs, University of Pittsburgh Department of Surgery, Pittsburgh, Pennsylvania; Ronald Pearl, MD, PhD, Professor and Chair, Anesthesia Department, Stanford University School of Medicine, Stanford, California; and Stuart Rich, MD, Professor of Medicine, Section of Cardiology, Center for Pulmonary Hypertension, University of Chicago, Chicago, Illinois.


2018 ◽  
Vol 17 (2) ◽  
pp. 80-85

Sonja Bartolome, MD, pulmonary hypertension specialist and Director of Liver Transplant Critical Care at University of Texas Southwestern Medical Center, Dallas, facilitated a comprehensive discussion among 4 additional clinical experts regarding their experiences with the broad-ranging issues related to treating patients with drug- and toxin-related pulmonary hypertension. Joining the call on May 3, 2018, were Vinicio de Jesus Perez, MD, Assistant Professor of Medicine and staff physician and Roham Zamanian, MD, Associate Professor of Medicine and Medical Director, from the Pulmonary Hypertension Clinic at Stanford University School of Medicine; Kelly Chin, MD, Director of the Pulmonary Hypertension Center at University of Texas Southwestern Medical Center; and Konstadina Darsaklis, MD, Assistant Professor at the University of Connecticut, and cardiologist at Hartford Hospital where she started the pulmonary hypertension clinic.


2005 ◽  
Vol 4 (2) ◽  
pp. 24-29
Author(s):  
Richard Channick ◽  
Hap Farber ◽  
Nicholas Hill ◽  
Robert Schilz

This discussion was moderated by Richard Channick, MD, Associate Professor of Medicine, Pulmonary and Critical Care Division, University of California, San Diego Medical Center, San Diego, California. The physicians participating included Hap Farber, MD, Director, Pulmonary Hypertension Center, Boston University Medical Center, Boston, Massachusetts; Nicholas Hill, MD, Chief, Pulmonary, Critical Care and Sleep Division, Tufts-New England Medical Center, Boston, Massachusetts; and Robert Schilz, PhD, DO, Director of Lung Transplantation and Advanced Lung Disease, and Assistant Professor of Medicine, Case Western Reserve University, Cleveland, Ohio.


2009 ◽  
Vol 8 (3) ◽  
pp. 163-171 ◽  
Author(s):  
Nicholas Hill ◽  
Omar A. Minai ◽  
Steven Nathan

Global experts in pulmonary hypertension attended the 2009 American College of Chest Physicians meeting in San Diego. While there, Dr Nicholas Hill, Chief of the Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, and Professor of Medicine, Tufts University, Boston; and Dr Steven Nathan, Medical Director, Lung Transplant and Advanced Lung Disease Program, Inova Fairfax Hospital, Falls Church, Virginia, talked with guest editor Dr Omar A. Minai to share their perspectives on current diagnosis, management, and future outlook for pulmonary hypertension patients with existing lung disease and hypoxia.


2002 ◽  
Vol 1 (3) ◽  
pp. 22-25
Author(s):  
Ivan Robbins ◽  
David Langleben ◽  
Michael McGoon ◽  
Abby Krichman

Ivan Robbins, MD, Director, Pulmonary Hypertension Center, Vanderbilt University, Nashville, Tennessee, conducted this discussion. The panel included David Langleben, MD, Director, Center for Pulmonary Vascular Disease, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; Michael McGoon, MD, Consultant in Cardiology, Mayo Clinic, Rochester, Minnesota; and Abby Krichman, RRT, Pulmonary Hypertension Coordinator, Duke University Medical Center, Durham, North Carolina.


Sign in / Sign up

Export Citation Format

Share Document